AbbVie 2014 Annual Report Download - page 104
Download and view the complete annual report
Please find page 104 of the 2014 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94 -
95 -
96 -
97 -
98 -
99 -
100 -
101 -
102 -
103 -
104 -
105 -
106 -
107 -
108 -
109 -
110 -
111 -
112 -
113 -
114 -
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
 |
 |
13NOV201221352027
Note 15 Segment and Geographic Area Information
.....................................................................................................................................................................................................................................................................................................................................................
AbbVie operates in one business segment—pharmaceutical products. Substantially all of AbbVie’s U.S.
sales are to three wholesalers. Outside the United States, products are sold primarily to health care
providers or through distributors, depending on the market served. Worldwide net sales of key products
were as follows:
years ended December 31 (in millions) 2014 2013 2012
HUMIRA $12,543 $10,659 $ 9,265
AndroGel 934 1,035 1,152
Kaletra 870 962 1,013
Synagis 835 827 825
Lupron 778 785 800
Synthroid 709 622 551
Sevoflurane 550 568 602
Creon 516 412 353
Dyslipidemia products 328 1,076 2,145
Duodopa 220 178 149
VIEKIRA 48 — —
All other 1,629 1,666 1,525
Net sales $19,960 $18,790 $18,380
Net sales to external customers, based on the country that sold the product, were as follows:
years ended December 31 (in millions) 2014 2013 2012
United States $10,845 $10,181 $10,435
Germany 1,035 911 756
The Netherlands 969 858 776
United Kingdom 722 606 552
France 584 540 500
Japan 581 625 718
Canada 551 538 500
Spain 534 543 525
Brazil 435 439 434
Italy 432 404 408
All other countries 3,272 3,145 2,776
Net sales $19,960 $18,790 $18,380
Long-lived assets include net property and equipment of $2.5 billion and $2.3 billion as of
December 31, 2014 and 2013, of which $1.8 billion and $1.6 billion, respectively, was located in the United
States and Puerto Rico and $551 million and $591 million, respectively, was located in Europe.
98 2014 Form 10-K